Smart Communications Simplifies Digital Archiving with Launch of SmartHUB™
Smart Communications ,the leading provider for cloud-based enterprise customer communications, today announced the availability of SmartHUB , a new cloud-native digital archiving solution designed to help businesses manage high-volume communications at scale, provide easy access to critical archived data, and ensure compliance with evolving industry regulations, regardless of sector or region. SmartHUB is built on the proven technology acquired through Smart Communications' April 2025 acquisition of Joisto, a leading digital archiving provider, and is now fully integrated into the Conversation Cloud™ platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617555406/en/
As businesses face growing data volumes, disconnected systems, and increasingly complex regulations, SmartHUB tackles these inefficiencies head-on. It enables seamless integration across systems and reduces IT burden and operational complexity, all while maintaining a strong focus on data security and compliance. With SmartHUB, businesses can trust that their data is securely managed and compliant with evolving regulations, ensuring both operational efficiency and peace of mind.
'By harnessing the power of cloud-native technology, we're enabling our customers to stay ahead of an increasingly complex and fast-moving regulatory environment, while significantly reducing operational risk, simplifying system complexity, and strengthening data security,' said Leigh Segall, CEO at Smart Communications. 'Just as we've redefined how enterprises manage customer communications and forms with modern, scalable solutions, we're now doing the same for archiving—giving organizations a trusted path to move away from legacy systems. SmartHUB will fundamentally transform how organizations store, access, and protect their most critical communications and customer data assets, unlocking new value that was previously out of reach.'
Designed on AWS and purpose-built for regulatory environments, SmartHUB also helps organizations proactively manage their legal obligations by offering immutable, audit-ready storage, comprehensive audit trails, and retention rule configurations across multiple jurisdictions with technology that meets requirements for GDPR, ISO 14641, and WCAG 2.1 Level AA. The platform simplifies the complexity of compliance across geographies, allowing enterprises to automate retention policies, track document lineage, and rapidly respond to audits or litigation.
' SmartHUB expands the Smart Communications value proposition significantly, offering a more complete end-to-end platform for managing the entire customer conversation, from creation and delivery to long-term, compliant storage and retrieval. It differentiates Smart Communications in a competitive market by directly addressing a critical pain point for its core customer base,' said Jim Lundy, Founder and CEO at Aragon Research.
SmartHUB uses flexible APIs and enterprise-level configuration management to integrate across other ERP, CRM, and HR systems, embedding compliance directly into core business workflows. This enables it to connect teams across customer service, IT, sales, claims handlers and more, reducing common friction points and latency when dealing with a customer service case, on-demand portal requests from end customers, or even to support compliance or litigation requests.
'SmartHUB was designed to meet the demands of today's communications landscape—where speed, security, and compliance are non-negotiable. With ingestion speeds of up to one million documents per hour and a cloud-native architecture, it eliminates the need for hardware while ensuring scalable, always-on access to critical data,' said Simon Tindal, CTO at Smart Communications. 'As AI transforms how archived communications are used—whether for real-time decisioning, self-service, or context-rich customer interactions—SmartHUB ensures that high-volume data is not just stored, but instantly retrievable and audit-ready.'
SmartHUB has proven success across financial services, insurance, telco, and utilities, making it an ideal fit for any organization with high customer communications volumes, complex compliance needs, or large customer service operations. As part of the Conversation Cloud, it simplifies archiving at scale and unlocks seamless integration with SmartCOMM™ and SmartIQ™ , offering teams a single, secure place to create, manage, and access all critical customer interactions.
To see how SmartHUB transforms archiving into an advantage, visit https://www.smartcommunications.com/products/smarthub/ .
About Smart Communications:
Smart Communications is the trusted choice for regulated enterprises looking to modernize complex processes and connect with customers in the moments that matter most. Its Conversation Cloud™ platform powers frictionless, compliant, digital-first experiences through omnichannel communications, intelligent data capture, and secure digital archival. More than 650 enterprises worldwide—including Zurich Insurance, Priority Health, The Pacific Financial Group, and The Bancorp—rely on Smart Communications to reduce compliance risk, boost operational efficiency, lower costs, and fast-track digital transformation that fuels business growth and elevates the customer experience. With more than 30 pre-built connectors, Smart Communications' cloud-native platform integrates effortlessly with the world's most trusted enterprise systems including Salesforce, Guidewire, DuckCreek, OneSpan, and Pega, enabling more than 60 billion mission-critical customer conversations globally, and driving faster time to value.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617555406/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
CORRECTION – Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows: MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States. This innovative diagnostic tool aims to enhance vascular health monitoring in the region. We are also pleased to announce that we are now in-network with Blue Cross Blue Shield of Arizona, allowing us to better serve this market. Additionally, we have secured contracts that enable the reimbursement of claims through United Healthcare, Aetna, Cigna, and Humana on a nationwide basis. These claims will be reimbursed on an out-of-network basis and apply to their PPO and Medicare Advantage plans. We are happy to share that the SmartVascular Dx test is also covered by Medicare. Why SmartVascular Should Be Your Go-To Test The SmartVascular Dx test is essential for the early detection of vascular disease, which is a significant health concern in many communities. Its capabilities enable timely and targeted interventions that can significantly improve health outcomes. Furthermore, we would like to remind our partners that we have collaborated with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact mjjohnson@ 866.299.8998
Yahoo
5 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
Anaergia S.r.l. Announces Agreement to Provide Infrastructure and Equipment for New Biomethane Plants in Spain
TREVIGLIO, Italy & BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. ('Anaergia', the 'Company', 'us', or 'our') (TSX:ANRG; OTCQX:ANRGF), through its subsidiary Anaergia S.r.l., has signed a Binding Agreement ('Agreement') with a leading Spanish company specializing in renewable gas infrastructure projects. Under the terms of the Agreement, Anaergia will provide a range of services as well as its cutting-edge technology and equipment for over 15 new biomethane production plants across Spain. Anaergia will be responsible for the supply and construction of concrete tanks with Triton™ digesters, a proprietary technology featuring a patented configuration that significantly enhances process efficiency. In addition, the company will supply advanced mixing systems, also part of its proprietary technology, along with other critical components to facilitate the seamless operations of the plants. Anaergia is to commence activities on the first project this month, with all the projects in the development plan expected to be fully operational and integrated into Spain's gas pipeline network within forty-eight months. Anaergia anticipates total revenue of C$184 million from this Agreement, making it the Company's largest capital sale to date. 'This agreement marks a significant milestone in advancing Spain's renewable energy sector, fostering economic growth and environmental sustainability. The scale of this historic Agreement for Anaergia highlights the advantages of our strategic focus on leveraging proprietary technologies for the benefit of our customers, and underscores our growing presence and activities in Europe,' said Assaf Onn, CEO of Anaergia. 'We are most excited about this opportunity to demonstrate the value of our innovative solutions and to support the global transition to renewable energy.' About Anaergia Anaergia is a pioneering technology company in the renewable natural gas (RNG) sector, with over 250 patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. We are committed to addressing a significant source of greenhouse gases (GHGs) through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today's critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by both third parties and Anaergia. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions. For further information please see: Forward-Looking Statements This news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia's current expectations regarding future events, including but not limited to, counterparty contractual performance, the capability of the Company's technology and performance with respect to the project objectives. Forward-looking information is based on a number of assumptions, including, but not limited to counterparty contractual performance, the full development, timing and funding of construction of the sixteen facilities, the capability of the Company's technology and performance with respect to the project objectives, the expected revenue from the agreement, and the sufficient sourcing of food waste and power generation. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, but are not limited to, the factors discussed under 'Risk Factors' in the Company's annual information form for the fiscal year ended December 31, 2024, and under 'Risks and Uncertainties' in the Company's most recent management's discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia's operations or financial results are included in Anaergia's reports on file with Canadian regulatory authorities.
